Kerry Anne Rambaran1, Steven W Fleming2, Jie An2, Samantha Burkhart2, Jakub Furmaga3, Kurt C Kleinschmidt3, A Michael Spiekerman4, Saeed K Alzghari2. 1. Department of Clinical and Administrative Sciences, School of Pharmacy, Keck Graduate Institute, Claremont, California. 2. Gulfstream Diagnostics, LLC, Dallas, Texas. 3. UT Southwestern Medical Center, Dallas, Texas; North Texas Poison Control Center, Parkland Health and Hospital System, Dallas, Texas. 4. Gulfstream Diagnostics, LLC, Dallas, Texas; Department of Clinical Pathology, Baylor Scott & White Health, Temple, Texas.
Abstract
BACKGROUND: U-47700 is a synthetic opioid developed by The Upjohn Company in the 1970s, which has recently appeared in the news and medical literature due to its toxicity. Currently, there are no clinical trial data assessing the safety of U-47700. OBJECTIVE: To describe the signs and symptoms of ingestion, laboratory testing, and treatment modalities for U-47700 intoxication. DISCUSSION: We searched PubMed, Embase, Web of Science, and EBSCO for articles using the term "U-47700" and "47700." The following inclusion criteria were used: had to be in English; full text; must involve humans; must be either a randomized control trial, prospective trial, retrospective analysis, case series, or case report; and must include clinical findings at presentation. We identified and extracted data from relevant articles. Ten relevant articles were included with 16 patients. Patients that died after overdose with U-47700 typically presented to the hospital with pulmonary edema. Patients who survived an overdose presented with decreased mental status and decreased respiratory rate suggestive of an opioid toxidrome. Patients also commonly had tachycardia. Immunoassays failed to identify U-47700, and the identification of U-47700 required the use of chromatographic and spectral techniques. CONCLUSION: We report the first clinical review of U-47700 intoxication.
BACKGROUND:U-47700 is a synthetic opioid developed by The Upjohn Company in the 1970s, which has recently appeared in the news and medical literature due to its toxicity. Currently, there are no clinical trial data assessing the safety of U-47700. OBJECTIVE: To describe the signs and symptoms of ingestion, laboratory testing, and treatment modalities for U-47700 intoxication. DISCUSSION: We searched PubMed, Embase, Web of Science, and EBSCO for articles using the term "U-47700" and "47700." The following inclusion criteria were used: had to be in English; full text; must involve humans; must be either a randomized control trial, prospective trial, retrospective analysis, case series, or case report; and must include clinical findings at presentation. We identified and extracted data from relevant articles. Ten relevant articles were included with 16 patients. Patients that died after overdose with U-47700 typically presented to the hospital with pulmonary edema. Patients who survived an overdose presented with decreased mental status and decreased respiratory rate suggestive of an opioid toxidrome. Patients also commonly had tachycardia. Immunoassays failed to identify U-47700, and the identification of U-47700 required the use of chromatographic and spectral techniques. CONCLUSION: We report the first clinical review of U-47700 intoxication.
Authors: Saeed K Alzghari; Steven W Fleming; Kerry Anne Rambaran; James E Long; Samantha Burkhart; Jie An; Jakub Furmaga Journal: Cureus Date: 2017-10-22
Authors: Renata Solimini; Simona Pichini; Roberta Pacifici; Francesco P Busardò; Raffaele Giorgetti Journal: Front Pharmacol Date: 2018-06-20 Impact factor: 5.810
Authors: Barbara Lovrecic; Mercedes Lovrecic; Branko Gabrovec; Marco Carli; Matteo Pacini; Angelo G I Maremmani; Icro Maremmani Journal: Int J Environ Res Public Health Date: 2019-01-09 Impact factor: 3.390
Authors: Enrico Gerace; Alberto Salomone; Clemente Luciano; Daniele Di Corcia; Marco Vincenti Journal: Front Pharmacol Date: 2018-07-10 Impact factor: 5.810
Authors: Frederike Nordmeier; Iryna Sihinevich; Adrian A Doerr; Nadja Walle; Matthias W Laschke; Thorsten Lehr; Michael D Menger; Peter H Schmidt; Markus R Meyer; Nadine Schaefer Journal: Arch Toxicol Date: 2021-10-03 Impact factor: 5.153